377 related articles for article (PubMed ID: 11359807)
21. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
22. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
24. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.
Koido S; Kashiwaba M; Chen D; Gendler S; Kufe D; Gong J
J Immunol; 2000 Nov; 165(10):5713-9. PubMed ID: 11067929
[TBL] [Abstract][Full Text] [Related]
25. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
26. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
27. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain.
Plunkett T; Graham R; Correa I; Sewell R; Miles D; Burchell J; Taylor-Papadimitriou J
Int J Cancer; 2004 May; 109(5):691-7. PubMed ID: 14999776
[TBL] [Abstract][Full Text] [Related]
28. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
29. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
30. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
31. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
Koido S; Tanaka Y; Chen D; Kufe D; Gong J
J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
33. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
34. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
35. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
36. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
37. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
[TBL] [Abstract][Full Text] [Related]
39. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
40. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
